LUTRATE DEPOT Powder and solvent for prolonged-release suspension for injection (2017)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Lutrate 1 month Depot 3.75 mg powder and solvent for prolonged-release suspension for injection.
Qualitative and quantitative composition
Each vial contains 3.75 mg of leuprorelin acetate (equivalent to 3.57 mg leuprorelin free base). 1 ml of reconstituted suspension contains 1.875 mg of leuprorelin acetate. Excipients with known effect: ...
Pharmaceutical form
Powder and solvent for prolonged-release suspension for injection. Powder: white to off-white powder. Solvent: clear transparent solution (pH 5.0–7.0).
Therapeutic indications
Metastatic prostate cancer. Locally advanced prostate cancer, as an alternative to surgical castration. As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced ...
Posology and method of administration
Posology The usual recommended dose of Lutrate 1 month Depot is 3.75 mg presented as a one month depot injection and administered as a single intramuscular injection every month. Lutrate 1 month Depot ...
Contraindications
Hypersensitivity to the active substance, luteinising hormone releasing hormone (LHRH) analogues or to any of the excipients listed in section 6.1. Reports of anaphylactic reactions to synthetic LHRH or ...
Special warnings and precautions for use
In the initial stages of Lutrate 1 month Depot treatment, as occurs during treatment with other LHRH agonists, a transient rise in levels of testosterone may occur. In some cases, this may be associated ...
Interaction with other medicinal products and other forms of interaction
No pharmacokinetic-based drug-drug interaction studies have been conducted with leuprorelin acetate. However, because leuprorelin acetate is a peptide that is primarily degraded by peptidase and not by ...
Fertility, pregnancy and lactation
Pregnancy Lutrate 1 month Depot is not indicated for use in pregnant women. Leuprorelin acetate injection may cause foetal harm when administered to a pregnant woman. Therefore, the possibility exists ...
Effects on ability to drive and use machines
No specific studies on the effects of Lutrate 1 month Depot on the ability to drive and use machines have been performed. However, the ability to drive and use machines may be impaired due to visual disturbances ...
Undesirable effects
Unless otherwise specified, the following safety profile of Lutrate 1 month Depot is based on the results of a phase III clinical trial in which prostate cancer patients were treated with six intramuscular ...
Overdose
There is no clinical experience with the effects of an acute overdose of Lutrate 1 month Depot or leuprorelin acetate. In clinical trials using daily subcutaneous leuprorelin acetate in patients with prostate ...
Pharmacodynamic properties
Pharmacotherapeutic group: Endocrine therapy. Hormones and related agents. Gonadotropin-releasing hormones analogues ATC code: L02AE02 Mechanism of action The chemical name of Leuprorelin acetate is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L- ...
Pharmacokinetic properties
Absorption Following three once-monthly injections of Lutrate 1 month Depot in a sample of prostate cancer patients (N=12), maximal leuprorelin acetate plasma concentration was similar among the three ...
Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity conducted with leuprorelin acetate. As expected from ...
List of excipients
Excipients of the lyophilizate (vial): Polysorbate 80 Mannitol (E421) Carmellose sodium (E466) Triethyl citrate Poly(DL-lactide-co-glycolide) (PLGA) Excipients of the solvent (prefilled syringe): Mannitol ...
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. No other solvent other than the sterile solvent provided for Lutrate 1 month Depot can be ...
Shelf life
Shelf life: 3 years unopened. Once reconstituted with the solvent the suspension should be administered immediately.
Special precautions for storage
Do not store above 25°C. Do not freeze. Store in the original package in order to protect from light. For storage conditions after reconstitution of the medicinal product, see section 6.3.
Nature and contents of container
The commercial kit includes: One (1) type I glass vial containing 3.75 mg of leuprorelin acetate as a freeze-dried powder, sealed with a bromobutyl stopper and an aluminium flip-off cap. One (1) type I ...
Special precautions for disposal and other handling
Method of administration The vial of Lutrate 1 month Depot microsphere powder should be reconstituted immediately prior to administration by intramuscular injection. Make sure an aseptic technique is followed. ...
Marketing authorization holder
Mercury Pharmaceuticals Limited, Capital House, 85 King William Street, London EC4N 7BL, United Kingdom
Marketing authorization number(s)
PL 12762/0509
Date of first authorization / renewal of the authorization
Date of first authorization: 16 June 2015
Date of revision of the text
04/07/2017
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
